Скачать или смотреть Anthem Biosciences IPO Review 2025 | Apply OR Avoid | CDMO Sector Growth Potential

Anthem Biosciences IPO could be the next breakout in India’s pharma-tech space.

This ₹3,400 crore IPO opens on July 14, and the company operates in the booming CDMO (Contract Development & Manufacturing Organization) sector — one of the most under-the-radar opportunities in the Indian market right now.

Just like IT in the 90s, CDMO is still early in India, but it’s growing fast.

Comment “IPO” if you want to know whether I’m applying

📈 Key financials:
– FY25 revenue up 30%
– PAT up 23%
– Solid ROE & ROCE
– Debt to equity = 0.05 (almost debt-free)

But here’s the catch:
– PE ratio = 70
– 100% offer for sale (no fresh capital into the business)

So the big question is — should you apply for this IPO?

In this video, I break down:
What is CDMO
Contract Development & Manufacturing Organization sector
CRDMO sector india
Why the sector could explode in the next 3 years
Whether Anthem’s valuation is justified
My personal decision — apply or skip?
Anthem Biosciences IPO
Anthem Biosciences IPO review
Anthem Biosciences IPO GMP
Anthem IPO 2025
Anthem Biosciences IPO analysis
Anthem Biosciences IPO review hindi
Anthem Biosciences IPO apply or avoid
Anthem Biosciences listing date
Anthem Biosciences allotment status
upcoming ipo 2025
pharma IPO 2025
CDMO stocks 2025
stock market IPO 2025

#Anthemipo #cdmo #upcomingipos #pharmastocks #indianstockmarket #ipoanalysis #anthembiociencesipo #ipo2025 #anthemipo2025 #crdmo

And don’t forget to 🎯subscribe ‪@mayankonmoney‬ for more fresh finance content.